title: Decreasing risk of pregnancy loss following chorionic villus sampling. Elimination of transabdominal chorionic villus sampling during the ninth week of pregnancy.
abstract: Chorionic villus sampling (CVS) is a method of obtaining fetal cells in the first trimester of pregnancy for genetic analysis. The transcervical (TC) approach was the first technique to be widely used. In the National Institute of Child Health and Human Development collaborative study the absolute loss rate following CVS (the total number of spontaneous abortions and neonatal deaths following CVS) was 4%. More recently the transabdominal (TA) approach has been introduced. This study compares the loss rates for the two approaches at various gestational ages for three 6-month periods following the addition of the TA approach with each other and with the loss rates prior to the introduction of TA CVS. We found that the percentage of pregnancy losses following TA CVS during the ninth week of gestation (63-69 days) was consistently higher than for TC CVS performed at the same gestational age. The loss rate for TC CVS has steadily decreased since the introduction of TA CVS after remaining the same for the two years prior to the introduction of the TA approach. After minimizing the number of TA CVS performed during the ninth week of gestation, the overall loss rate during the most recent 6-month period has been reduced to 0.94%. We conclude that the lowest loss rate following CVS can be obtained if both the TA and TC methods are available, and that the number of TA procedures performed during the ninth week of gestation is minimized.
authors: Reproductive Genetics Institute, Illinois Masonic Medical Center, Chicago.
authors: N A
authors: NA
authors: Ginsberg
authors: M
authors: M
authors: Applebaum
authors: N
authors: N
authors: Bozorgi
authors: A V
authors: AV
authors: Cadkin
authors: Y
authors: Y
authors: Verlinsky
authors: C M
authors: CM
authors: Strom
mesh_terms: D000022:Abortion, Spontaneous / Q000209:etiology*; D015193:Chorionic Villi Sampling / Q000009:adverse effects* / Q000379:methods; D005260:Female; D005313:Fetal Death / Q000209:etiology; D006801:Humans; D011247:Pregnancy; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First